NCT07406633 2026-04-17
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
Phase 2 Recruiting
Clinical Trials
45 trialsNCT06090669 2026-04-16
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT06124157 2026-04-14
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT04971226 2026-04-06
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
Novartis
Phase 3 Active not recruiting
NCT03516279 2026-04-03
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease
Eastern Cooperative Oncology Group
Phase 2 Active not recruiting
NCT01742299 2026-04-01
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Novartis
Phase 4 Active not recruiting
NCT04307576 2026-03-27
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
Phase 3 Recruiting
NCT07171203 2026-03-25
Neoadjuvant Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor
University of California, San Diego
Phase 1 Recruiting
NCT00070499 2026-03-23
Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT00044304 2026-03-16
Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome
National Institutes of Health Clinical Center (CC)
Phase 2 Active not recruiting
NCT00421317 2026-03-13
O-Mel-Inib
Centre Oscar Lambret
Phase 2 Terminated
NCT01046487 2026-03-13
PALANGI3
Centre Oscar Lambret
Phase 1 Completed
NCT04877522 2026-03-06
Asciminib Roll-over Study
Novartis
Phase 4 Recruiting
NCT03007147 2026-02-23
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Phase 3 Active not recruiting
NCT07413263 2026-02-18
Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients
Assiut University
Not yet recruiting
NCT05493215 2026-02-17
Imatinib TDM in GIST
University of Kentucky
Phase 2 Recruiting
NCT05381753 2026-02-11
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
CStone Pharmaceuticals
Completed
NCT06655246 2026-02-05
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology, Inc.
Phase 1 Recruiting
NCT06889168 2026-01-21
LAMP-2
Columbia University
Phase 1 Recruiting
NCT05245968 2026-01-20
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Taiho Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT05152472 2026-01-08
ATEZOGIST
Centre Leon Berard
Phase 2 Recruiting
NCT04626024 2025-12-19
TOKIN
Baylor College of Medicine
Phase 2 Recruiting
NCT03654768 2025-12-18
Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
SWOG Cancer Research Network
Phase 2 Active not recruiting
NCT02881086 2025-12-16
Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment
Goethe University
Phase 3 Completed
NCT01991379 2025-12-04
MEK162 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Memorial Sloan Kettering Cancer Center
Phase 1/2 Active not recruiting
NCT03589326 2025-11-26
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
Takeda
Phase 3 Active not recruiting
NCT04070443 2025-11-18
TIPI
Centre Leon Berard
Phase 2 Active not recruiting
NCT03578367 2025-11-10
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Phase 2 Completed
NCT01316250 2025-10-02
Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous Leukemia
American University of Beirut Medical Center
Phase NA Completed
NCT07022743 2025-09-05
Improving Treatment Outcomes in Chronic Myeloid Leukaemia Patients Using Imatinib and Artesunate Combination Therapy
Obafemi Awolowo University
Phase 2 Active not recruiting
NCT04598009 2025-09-03
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma
University of California, San Francisco
Phase 2 Recruiting
NCT05816785 2025-09-03
Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
University of Wisconsin, Madison
Phase EARLY_PHASE1 Active not recruiting
NCT00015847 2025-08-22
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT03112603 2025-08-12
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
Phase 3 Completed
NCT05385549 2025-08-08
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Asan Medical Center
Phase 2 Recruiting
NCT04838041 2025-07-30
Protocol Number: HJKC3-0003. Treatment Free Remission After Asciminib Based Therapy in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation
Medical College of Wisconsin
Phase 2 Recruiting
NCT07091019 2025-07-29
ASC4REAL-2
Novartis
Not yet recruiting
NCT05722795 2025-07-09
I-CONIC
Vastra Gotaland Region
Phase NA Recruiting
NCT03469011 2025-06-27
A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid Cancer.
AHS Cancer Control Alberta
Phase 1 Terminated
NCT00476190 2025-06-12
ALL Adult Consortium Trial: Adult ALL Trial
Dana-Farber Cancer Institute
Phase 2 Completed
NCT01860456 2025-06-05
TIKlet
University of Pisa
Completed
NCT01751425 2025-06-03
Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT05413915 2025-05-21
Asciminib Used in Consolidation With Imatinib vs. Imatinib to Achieve TFR in CP-CML
Sir Mortimer B. Davis - Jewish General Hospital
Phase 3 Active not recruiting
NCT06962254 2025-05-08
Imatinib and Trametinib for KRAS-mutated Solid Tumor
China Medical University Hospital
Phase 1 Recruiting
NCT05071482 2025-05-01
Flumatinib Versus Imatinib Combined With Chemotherapy for de Novo Ph+ ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Terminated